Anal Carcinoma

19 registered clinical trials studyying Anal Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer NCT07407647	Ohio State University Comprehensive Cancer Center	Phase 2
Recruiting	Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176	Jonsson Comprehensive Cancer Center	Phase 1
Recruiting	Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers NCT05663502	AIDS Malignancy Consortium	—
Unknown	HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor NCT05787535	HRYZ Biotech Co.	Phase 1
Recruiting	Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer NCT05438836	Herlev Hospital	—
Completed	Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced NCT04505553	University of Washington	Phase 2
Active Not Recruiting	Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876	SOLTI Breast Cancer Research Group	Phase 2
Terminated	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034	Incyte Corporation	Phase 1
Active Not Recruiting	Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiatio NCT04713618	Ohio State University Comprehensive Cancer Center	—
Active Not Recruiting	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Tria NCT04230759	Goethe University	Phase 2
Unknown	Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) NCT03241680	Universidade do Vale do Sapucai	N/A
Completed	Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor? NCT03469596	Fondation Hôpital Saint-Joseph	—
Active Not Recruiting	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067	Merck Sharp & Dohme LLC	Phase 2
Terminated	Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lym NCT02408861	National Cancer Institute (NCI)	Phase 1
Unknown	Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy NCT02369939	University of Erlangen-Nürnberg Medical School	Phase 3
Active Not Recruiting	Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men NCT02816879	Jonsson Comprehensive Cancer Center	N/A
Unknown	Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients NCT01877135	French Society of Coloproctology	—
Active Not Recruiting	Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 NCT00867464	National Cancer Institute (NCI)	—
Completed	Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced C NCT00423254	Mannkind Corporation	Phase 1